Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

6,267JPY
23 Jun 2017
Change (% chg)

¥2 (+0.03%)
Prev Close
¥6,265
Open
¥6,298
Day's High
¥6,303
Day's Low
¥6,254
Volume
646,800
Avg. Vol
799,976
52-wk High
¥7,280
52-wk Low
¥5,366

4523.T

Chart for 4523.T

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's businesses include pharmaceutical business and other business. The Company's segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South... (more)

Overall

Beta: 0.66
Market Cap(Mil.): ¥1,857,992.00
Shares Outstanding(Mil.): 296.57
Dividend: 70.00
Yield (%): 2.39

Financials

  4523.T Industry Sector
P/E (TTM): 45.59 14.08 19.12
EPS (TTM): 137.42 -- --
ROI: 5.26 -6.75 -5.05
ROE: 6.80 -6.20 -4.29

BRIEF-Ewopharma announces commercial partnership with Eisai

* Ewopharma says it will commercialise Halaven (eribulin mesylate) in nine countries within European Union and in two countries outside of EU

Jun 22 2017

BRIEF-Positive topline results show Eisai's Lenvatinib meets primary endpoint

* Positive topline results of large phase 3 trial show Eisai's lenvatinib meets primary endpoint in unresectable hepatocellular carcinoma

Jan 25 2017

Swiss stocks - Factors to watch on Jan 16

ZURICH, Jan 16 The Swiss blue-chip SMI was seen opening 0.2 percent easier at 8,436 points on Monday, according to premarket indications by bank Julius Baer .

Jan 16 2017

Halozyme's pancreatic cancer drug succeeds in mid-stage trial

Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.

Jan 05 2017

More From Around the Web

Earnings vs. Estimates